Summit Therapeutics Inc. (SMMT)
| Market Cap | 5.29B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -116.03M |
| Shares Out | 701.97M |
| EPS (ttm) | -0.00 |
| PE Ratio | 20.67 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,665,487 |
| Open | 8.14 |
| Previous Close | 8.14 |
| Day's Range | 7.53 - 8.19 |
| 52-Week Range | 1.52 - 11.25 |
| Beta | -1.03 |
| Analysts | Strong Buy |
| Price Target | 13.50 (+79.05%) |
| Earnings Date | Aug 7, 2024 |
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes c... [Read more]
Analyst Forecast
According to 2 analysts, the average rating for SMMT stock is "Strong Buy." The 12-month stock price forecast is $13.5, which is an increase of 79.05% from the latest price.
News
Summit Therapeutics Appoints Jeff Huber, Transformational Google and GRAIL Executive, to its Board of Directors
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Jeff Huber has been appointed to its Board of Directors, effective imm...
Summit Therapeutics stock rallies as institutional buyer loads up on shares
Summit Therapeutics Inc (NASDAQ: SMMT) says it raised $200 million via an offer it accepted from an institutional investor on Monday. Shares of the biotech firm are up 12% at writing.
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Company received and accepted an unsolicited offer from an institu...
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that the Journal of the American Medical Association (JAMA) published a manuscrip...
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) announced that, on May 24, 2024, our partner, Akeso Inc. (Akeso, HKEX Code: 9926.HK), recei...
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of...
Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster
Shares of Summit Therapeutics Inc. SMMT, +272.06% jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stag...
Summit Therapeutics cancer therapy succeeds in late-stage China study
Summit Therapeutics said on Thursday its experimental therapy to treat patients with a type of lung cancer met the main goal of a late-stage study conducted in China.
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that the Phase III clinical trial, HARMONi-2 or AK112-303, met its primary ...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on its operational progress for ...
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its first quarter 2024 financial results and provide...
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Mostafa Ronaghi, PhD, has been appointed to its Board of Directors, ef...
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Stifel 2024 Targeted Oncolog...
Illumina CFO Goswami to depart, Summit Therapeutics' Dhingra named successor
Illumina said on Tuesday Chief Financial Officer Joydeep Goswami would leave the gene sequencing company and would be succeeded by former Summit Therapeutics' executive Ankur Dhingra.
Illumina appoints Ankur Dhingra Chief Financial Officer, Jakob Wedel Chief Strategy and Corporate Development Officer
Joydeep Goswami to serve as advisor through June 30 Illumina reaffirms Q1 2024 and full-year 2024 financial guidance SAN DIEGO , April 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global l...
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced promising data for its novel, potential first-in-class investigational bisp...
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that data for its novel, potential first-in-class investigational bispecifi...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
NEW YORK , March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Summit Therapeutics Inc. ("Summit" or the "Company") (NASDAQ: SMMT). Such investors are advis...
Shareholders that lost money on Summit Therapeutics Inc. (SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Lost Money on Summit Therapeutics Inc.(SMMT)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
NEW YORK, NY / ACCESSWIRE / March 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Summit Therapeutics Being Investigated on Behalf of Summit Therapeutics Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Lost Money on Summit Therapeutics Inc.(SMMT)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning poss...
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the Barclays 26th Annual Global ...
Shareholders that lost money on Summit Therapeutics Inc.(SMMT) should contact Levi & Korsinsky about Securities Fraud Investigation - SMMT
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...
Levi & Korsinsky Announces an Investigation on Behalf of Summit Therapeutics Inc. (SMMT) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / February 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Summit Therapeutics Inc. ("Summit Therapeutics") (NASDAQ:SMMT) concerning ...